Gulley JL - Search Results

1

Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer.

Chalfin HJ, Pramparo T, Mortazavi A, Niglio SA, Schonhoft JD, Jendrisak A, Chu YL, Richardson R, Krupa R, Anderson AKL, Wang Y, Dittamore R, Pal SK, Lara PN, Stein MN, Quinn DI, Steinberg SM, Cordes LM, Ley L, Mallek M, Sierra Ortiz O, Costello R, Cadena J, Diaz C, Gulley JL, Dahut WL, Streicher H, Wright JJ, Trepel JB, Bottaro DP, Apolo AB. Chalfin HJ, et al. Among authors: gulley jl. Clin Cancer Res. 2021 Mar 1;27(5):1391-1398. doi: 10.1158/1078-0432.CCR-20-2891. Epub 2020 Dec 1. Clin Cancer Res. 2021. PMID: 33262136 Free PMC article.

2

Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen.

Terasawa H, Tsang KY, Gulley J, Arlen P, Schlom J. Terasawa H, et al. Clin Cancer Res. 2002 Jan;8(1):41-53. Clin Cancer Res. 2002. PMID: 11801539

3

Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer.

Gulley J, Chen AP, Dahut W, Arlen PM, Bastian A, Steinberg SM, Tsang K, Panicali D, Poole D, Schlom J, Michael Hamilton J. Gulley J, et al. Prostate. 2002 Oct 1;53(2):109-17. doi: 10.1002/pros.10130. Prostate. 2002. PMID: 12242725 Clinical Trial.

4

Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer.

Horne MK 3rd, Figg WD, Arlen P, Gulley J, Parker C, Lakhani N, Parnes H, Dahut WL. Horne MK 3rd, et al. Pharmacotherapy. 2003 Mar;23(3):315-8. doi: 10.1592/phco.23.3.315.32106. Pharmacotherapy. 2003. PMID: 12627929

5

Pulmonary toxicity during prostate cancer treatment with docetaxel and thalidomide.

Behrens RJ, Gulley JL, Dahut WL. Behrens RJ, et al. Among authors: gulley jl. Am J Ther. 2003 May-Jun;10(3):228-32. doi: 10.1097/00045391-200305000-00011. Am J Ther. 2003. PMID: 12756431

6

The emerging role of bisphosphonates in prostate cancer.

Posadas EM, Dahut WL, Gulley J. Posadas EM, et al. Am J Ther. 2004 Jan-Feb;11(1):60-73. doi: 10.1097/00045391-200401000-00012. Am J Ther. 2004. PMID: 14704597 Review.

7

Novel therapeutic strategies in prostate cancer.

Retter AS, Gulley JL, Dahut WL. Retter AS, et al. Among authors: gulley jl. Cancer Biol Ther. 2004 Apr;3(4):371-6. doi: 10.4161/cbt.3.4.725. Epub 2004 Apr 29. Cancer Biol Ther. 2004. PMID: 14726702 Free article. Review.

8

Novel approaches to treating the asymptomatic hormone-refractory prostate cancer patient.

Gulley J, Dahut WL. Gulley J, et al. Urology. 2003 Dec 29;62 Suppl 1:147-54. doi: 10.1016/j.urology.2003.08.003. Urology. 2003. PMID: 14747053 Review.

9

A human cytotoxic T-lymphocyte epitope and its agonist epitope from the nonvariable number of tandem repeat sequence of MUC-1.

Tsang KY, Palena C, Gulley J, Arlen P, Schlom J. Tsang KY, et al. Clin Cancer Res. 2004 Mar 15;10(6):2139-49. doi: 10.1158/1078-0432.ccr-1011-03. Clin Cancer Res. 2004. PMID: 15041735

10

National Cancer Institute intramural approach to advanced prostate cancer.

Arlen PM, Figg WD, Gulley J, Cox MC, Linehan WM, Dahut W. Arlen PM, et al. Clin Prostate Cancer. 2002 Dec;1(3):153-62. doi: 10.3816/cgc.2002.n.017. Clin Prostate Cancer. 2002. PMID: 15046690

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

389 results

Search Page

Filters